Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Fort Sheridan Advisors LLC

Fort Sheridan Advisors LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 18.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 7,130 shares of the biopharmaceutical company’s stock after selling 1,655 shares during the quarter. Fort Sheridan Advisors LLC’s holdings in Gilead Sciences were worth $518,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in GILD. Morgan Stanley lifted its position in shares of Gilead Sciences by 18.3% during the 2nd quarter. Morgan Stanley now owns 10,989,872 shares of the biopharmaceutical company’s stock valued at $756,765,000 after acquiring an additional 1,702,366 shares during the period. Keudell Morrison Wealth Management increased its stake in shares of Gilead Sciences by 4.5% during the 3rd quarter. Keudell Morrison Wealth Management now owns 10,727 shares of the biopharmaceutical company’s stock worth $749,000 after purchasing an additional 458 shares in the last quarter. EagleClaw Capital Managment LLC increased its stake in shares of Gilead Sciences by 1.2% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 42,870 shares of the biopharmaceutical company’s stock worth $2,993,000 after purchasing an additional 516 shares in the last quarter. Richard Bernstein Advisors LLC increased its stake in shares of Gilead Sciences by 6.3% during the 3rd quarter. Richard Bernstein Advisors LLC now owns 34,359 shares of the biopharmaceutical company’s stock worth $2,399,000 after purchasing an additional 2,024 shares in the last quarter. Finally, Sawtooth Solutions LLC increased its stake in shares of Gilead Sciences by 14.5% during the 3rd quarter. Sawtooth Solutions LLC now owns 15,875 shares of the biopharmaceutical company’s stock worth $1,109,000 after purchasing an additional 2,013 shares in the last quarter. Hedge funds and other institutional investors own 80.16% of the company’s stock.

Shares of NASDAQ GILD traded down $0.11 during trading on Friday, hitting $62.37. 9,514,690 shares of the company traded hands, compared to its average volume of 8,039,876. Gilead Sciences, Inc. has a 1 year low of $57.19 and a 1 year high of $74.12. The company has a 50-day moving average price of $60.61 and a 200-day moving average price of $65.27. The firm has a market capitalization of $78.23 billion, a P/E ratio of 17.42, a P/E/G ratio of 0.43 and a beta of 0.38. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.35. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.28 billion. During the same period in the previous year, the company earned $2.08 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 6.62 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 29th. Investors of record on Wednesday, June 15th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Tuesday, June 14th. This represents a $2.92 annualized dividend and a dividend yield of 4.68%. Gilead Sciences’s payout ratio is 81.56%.

A number of research analysts have recently weighed in on GILD shares. Truist Financial dropped their price objective on shares of Gilead Sciences from $77.00 to $75.00 and set a “hold” rating for the company in a research note on Wednesday, February 2nd. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 12th. Barclays dropped their price objective on shares of Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a research note on Thursday, March 10th. StockNews.com assumed coverage on shares of Gilead Sciences in a research note on Thursday, March 31st. They issued a “buy” rating for the company. Finally, Royal Bank of Canada lifted their target price on shares of Gilead Sciences from $76.00 to $77.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $72.93.

In related news, EVP Brett A. Pletcher sold 3,634 shares of Gilead Sciences stock in a transaction on Friday, March 11th. The shares were sold at an average price of $58.24, for a total transaction of $211,644.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.